XL 765 - CAS 1349796-36-6
Catalog number: B0084-462702
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
XL 765 is a PI3K inhibitor used for the treatment of cancers. It also suppresses DNA-PK and mTOR.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462702 50 mg $399 In stock
Bulk Inquiry
SAR 245409; N-[4-[[[3-[(3,5-Dimethoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-3-methoxy-4-methylbenzamide; N-(4-(N-(3-((3,5-Dimethoxyphenyl)amino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide
Canonical SMILES:
1.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Thijssen R;Ter Burg J;van Bochove GG;de Rooij MF;Kuil A;Jansen MH;Kuijpers TW;Baars JW;Virone-Oddos A;Spaargaren M;Egile C;van Oers MH;Eldering E;Kersten MJ;Kater AP Leukemia. 2016 Feb;30(2):337-45. doi: 10.1038/leu.2015.241. Epub 2015 Sep 4.
The phosphoinositide 3-kinases (PI3Ks) are critical components of the B-cell receptor (BCR) pathway and have an important role in the pathobiology of chronic lymphocytic leukemia (CLL). Inhibitors of PI3Kδ block BCR-mediated cross-talk between CLL cells and the lymph node microenvironment and provide significant clinical benefit to CLL patients. However, the PI3Kδ inhibitors applied thus far have limited direct impact on leukemia cell survival and thus are unlikely to eradicate the disease. The use of inhibitors of multiple isoforms of PI3K might lead to deeper remissions. Here we demonstrate that the pan-PI3K/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) was more pro-apoptotic to CLL cells--irrespective of their ATM/p53 status--than PI3Kα or PI3Kδ isoform selective inhibitors. Furthermore, SAR245409 blocked CLL survival, adhesion and proliferation. Moreover, SAR245409 was a more potent inhibitor of T-cell-mediated production of cytokines, which support CLL survival. Taken together, our in vitro data provide a rationale for the evaluation of a pan-PI3K inhibitor in CLL patients.
2.Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C;Zhang B;Liu X;Ma S;Yang Y;Yao Y;Feng M;Bao X;Li G;Wang J;Guo K;Ma W;Xing B;Lian W;Xiao J;Cai F;Zhang H;Wang R Endocrinology. 2013 Mar;154(3):1247-59. doi: 10.1210/en.2012-1908. Epub 2013 Feb 5.
Invasive pituitary adenomas (PAs) are often refractory to standard therapy and salvage treatment with temozolomide (TMZ). Hyperactivation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway contributes to chemotherapy resistance in many cancers. XL765, a novel dual-PI3K/mTOR inhibitor, has recently shown its efficacy as a monotherapy and in combination with conventional therapeutics in many cancers. The hyperactive PI3K/AKT/mTOR pathway frequently occurs in invasive PAs. In this study, we investigated whether XL765 sensitizes PA cells to TMZ in vitro and in vivo. Experiments were carried out to evaluate the effect of XL765 and TMZ alone or in combination on cell proliferation and apoptosis of PA cell lines (αT3-1, GH3, and MMQ) in vitro as well as the tumor growth and serum GH and prolactin secretions in a GH3 xenograft tumor model of female nude mice. XL765 and TMZ synergistically inhibited the growth of PA cell lines and induced apoptosis. Combination of XL765 and TMZ synergistically inhibited tumor growth, decreased serum GH and prolactin levels, and reduced the sacrifice rate of GH3 xenograft tumor models without increased systemic side effects.
3.Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Yu P;Laird AD;Du X;Wu J;Won KA;Yamaguchi K;Hsu PP;Qian F;Jaeger CT;Zhang W;Buhr CA;Shen P;Abulafia W;Chen J;Young J;Plonowski A;Yakes FM;Chu F;Lee M;Bentzien F;Lam ST;Dale S;Matthews DJ;Lamb P;Foster P Mol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709. Epub 2014 Mar 14.
Activation of the PI3K (phosphoinositide 3-kinase) pathway is a frequent occurrence in human tumors and is thought to promote growth, survival, and resistance to diverse therapies. Here, we report pharmacologic characterization of the pyridopyrimidinone derivative XL765 (SAR245409), a potent and highly selective pan inhibitor of class I PI3Ks (α, β, γ, and δ) with activity against mTOR. Broad kinase selectivity profiling of >130 protein kinases revealed that XL765 is highly selective for class I PI3Ks and mTOR over other kinases. In cellular assays, XL765 inhibits the formation of PIP(3) in the membrane, and inhibits phosphorylation of AKT, p70S6K, and S6 phosphorylation in multiple tumor cell lines with different genetic alterations affecting the PI3K pathway. In a panel of tumor cell lines, XL765 inhibits proliferation with a wide range of potencies, with evidence of an impact of genotype on sensitivity. In mouse xenograft models, oral administration of XL765 results in dose-dependent inhibition of phosphorylation of AKT, p70S6K, and S6 with a duration of action of approximately 24 hours. Repeat dose administration of XL765 results in significant tumor growth inhibition in multiple human xenograft models in nude mice that is associated with antiproliferative, antiangiogenic, and proapoptotic effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products

(CAS: 1639417-53-0)

RP-6530, a purine derivative, has been found to be a PI3Kδ/γ inhibitor that could exhibit cytotoxicity in some lymphoma primary cells so that is significant in ...

CAS 934529-30-3 XL PI3K/mTOR inhibitor

XL PI3K/mTOR inhibitor
(CAS: 934529-30-3)

An orally bioactive PI3K/mTOR tyrosine kinase inhibitor.

(CAS: 1268454-23-4)

MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.

CAS 648449-76-7 AS-604850

(CAS: 648449-76-7)

AS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for P...

CAS 1254036-66-2 GSK2292767

(CAS: 1254036-66-2)

GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials....

GSK-2269557 HCl salt
(CAS: 1254036-77-5)

GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the close...

CAS 1404231-34-0 ON 146040

ON 146040
(CAS: 1404231-34-0)

ON 146040 was highly potent in killing hematologic tumor cells with IC50 values in the 150 to 1,000 nM range. In biochemical testing, ON 146040 inhibited PI3K α...

(CAS: 1254036-71-9)

GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asth...

(CAS: 1608125-21-8)

AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.

CAS 900185-02-6 PIK-294

(CAS: 900185-02-6)

PIK-294 is a potent PI3K inhibitor.

CAS 870281-34-8 Acalisib

(CAS: 870281-34-8)

Acalisib, also known as GS-9820,  is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) ...

(CAS: 1532533-67-7)

TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which is approximately 1000 -fold selective over alpha isoform, >30-...

CAS 944396-07-0 BKM120

(CAS: 944396-07-0)

BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...

CAS 870281-82-6 CAL-101 (GS-1101)

CAL-101 (GS-1101)
(CAS: 870281-82-6)

Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

CAS 1172118-03-4 PI3Ky inhibitor 1

PI3Ky inhibitor 1
(CAS: 1172118-03-4)

PI3Ky inhibitor 1 is a potent PI3Ky inhibitor.

PI3Kα inhibitor 1
(CAS: 1235449-52-1)

PI3Kα inhibitor 1 is an inhibitor of PI3Kα as well as HDAC and probably have antineoplastic activity. IC50: <0.1 μM.

copanlisib hydrochloride
(CAS: 1402152-13-9)

Copanlisib hydrochloride is a potent inhibitor of Class I phosphoinositide 3-kinase which showed a therapeutic effect on non-Hodgkin lymphoma. It was approved t...

CAS 957054-30-7 GDC0941

(CAS: 957054-30-7)

GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM.

CAS 1013098-90-2 PI3Kα/mTOR-IN-1

(CAS: 1013098-90-2)

PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).

CAS 677297-51-7 TG100-115

(CAS: 677297-51-7)

TG100-115 is a potent and selective PI3K γ and -δ inhibitor (IC50 values of 83 and 235 nM, respectively) with no effect on PI3Kα or -β (IC50 values > 1 μM). As ...

Chemical Structure

CAS 1349796-36-6 XL 765

Quick Inquiry

Verification code

Featured Items